Introduction

Date 29 September 2014
Event ESMO 2014
Session Anti-EGFR or anti-VEGF in first-line RAS wild-type metastastic CRC patients: Can we define an "optimal" treatment strategy?
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Dirk Arnold
Authors D. Arnold
  • Department Of Medical Oncology, Tumor Biology Center, 79106 - Freiburg/DE